Mazzanti A, et al. - Researchers examined patients with Brugada Syndrome (BrS) to investigate if low-dose quinidine could attenuate the occurrence of life-threatening arrhythmic events (LAEs) at follow-up, as compared to no therapy, in a population of both high-risk survivors of LAE and lower risk patients asymptomatic for LAEs. They also determined if low-dose quinidine could reduce the arrhythmic burden in the high-risk group of cardiac arrest survivors. In patients with BrS who had already survived an LAE, a reduction in recurrent LAEs in the long-term was achieved with low-dose quinidine, with few side effects, as demonstrated for the first time in this study. Recurrent life-threatening arrhythmias were experienced by 15% of patients symptomatic for LAEs, while they were on-treatment, this implies that quinidine cannot serve as a substitute to implantable defibrillators in high-risk individuals.